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INTRODUCTION
Originating in the mid 1600s in Germany, intrave-
nous infusion has progressed considerably from the once 
used feather quills to greater than a million chemothera-
peutic infusions per day.1,2 Intravenous therapy (IVT) is 
prevalent in every medical specialty, with a diversity of ap-
plications including anesthesia, rehydration, transfusion, 
drug delivery, parenteral nutrition, central venous pres-
sure monitoring, dialysis, contrast imaging, and countless 
other important applications.3 With such substantial use, 
infiltration and extravasation injuries to the soft tissue are 
commonplace, occurring in up to 6% of patients.4
Iatrogenic complications of IVT include infection, 
phlebitis, infiltration, extravasation, soft-tissue necrosis, 
and compartment syndrome.3,5 Severity often correlates 
with the characteristics of the injected solution. Though 
the terms are often used interchangeably, strictly speak-
ing, infiltration refers to leakage of nonvesicant (nonir-
ritating) solution into the extravascular space,6,7 while 
extravasation involves a vesicant (irritating) solution.6
Various agents induce soft-tissue injury through dis-
tinct mechanisms. Vasoactive agents induce vasocon-
striction causing ischemia and subsequent necrosis.7 
Electrolyte-rich solutions alter the electrical potential 
and subsequent tone in pre- and postcapillary sphincters 
leading to ischemia.7 Hyperosmolar solutions cause a 
fluid shift from vascular and cellular compartments into 
the surrounding tissues leading to elevated compartment 
pressures and potentially compartment syndrome.7,8 
Finally, cytotoxic solutions are directly toxic to the sur-
rounding tissues.
Plastic surgeons and trainees are often on the fore-
front of management of these injuries.5 Treatment in the 
inpatient setting is not an emphasized part of the standard 
plastic surgery curriculum, and consequently, many train-
ees remain unaware of interventions outside the realm 
of antibiotic ointments, debridement, and soft-tissue re-
construction. This is despite compelling data that shows 
a benefit with certain early interventions. Adding to the 
confusion with the standard of care is the variation and 
inconsistency among many hospital-specific guidelines,9,10 
as many treatments have only an anecdotal basis. As an 
essential component of the wound management team in 
many settings, plastic surgeons should be knowledgeable 
and involved in the development of guidelines to mini-
mize iatrogenic morbidity. The objective of this article was 
to provide an evidence-based review of extravasation inju-
ries relevant to plastic surgeons and trainees.
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Intravenous therapy is a common practice among many specialties. Intravenous 
therapy extravasation is a potential complication to such therapy. Hospitals without 
a dedicated wound care team trained in these interventions will often default to 
plastic surgical consultation, making an understanding of available interventions 
essential to the initial evaluation and management of these injuries. The goal of 
this article was to provide plastic surgeons and health care providers with a general 
overview of the acute management of intravenous infiltration and extravasation 
injuries. Though the decision for surgical versus nonsurgical management is of-
ten a clear one for plastic surgeons, local interventions, and therapies are often 
indicated and under-utilized in the immediate postinfiltration period. Thorough 
knowledge of these interventions should be a basic requirement in the armamen-
tarium of plastic surgery consultants. (Plast Reconstr Surg Glob Open 2018;6:e1743; 
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Immediate symptoms of IVT extravasation may in-
clude blanching of the skin, discomfort, edema, changes 
in IV flow, and fluid leakage (Table 1).3 Early recognition 
is important. There are multiple classifications of extrava-
sations. The United States Department of Health and 
Human Services, National Cancer institute, and National 
Institute of Health published the Common Terminology 
Criteria for Adverse Events (Version 4.0 of May 2009), 
which includes a devised 5-point grading system for ex-
travasation (Table 2).11,12
The peripheral intravenous infiltration and extravasation 
scale is a more recently developed scale, dependent upon 
the proportion of appendage affected rather than exclusively 
the length of the infiltrated area. This ratio is determined 
by measuring the maximum dimension of edema (width or 
length) and dividing by the length of the appendage (ax-
illa to longest finger or groin to longest toe).13 There are 3 
grades (Table 3): mild (< 30% affected), moderate (30–60% 
affected), and severe (> 60% affected), with suggested inter-
ventions based on the severity of limb involvement.
Nonpharmacologic Management
Following identification, IVT should immediately be 
discontinued while keeping the catheter in place, allow-
ing for potential aspiration of the infiltrated agent with 3–
5 mL of blood using a 10 mL syringe.14,15 A reversal agent, 
if available, may also be administered via the catheter, fol-
lowed by removal. Maneuvers to reduce edema, such as 
limb elevation, should be instituted.
Thermal compresses are commonly utilized in the 
acute period, though their efficacy outside of increasing 
patient comfort remains anecdotal with no controlled 
studies.16,17 They are typically administered for 20 min-
utes 4 times per day for 1–2 days.15 In theory, cold com-
presses elicit local vasoconstriction, which can reduce 
pain, local inflammation, and the further spread of the 
infused agent—useful for infiltration by hyperosmolar 
solutions such as Total Parenteral Nutrition (TPN). 
Cold compresses are contraindicated for cases of infil-
tration by vasopressors, vinca alkaloids, and epipodo-
phyllotoxins (etoposide) due to evidence of subsequent 
further deterioration.9,11,15 In contrast, warm compresses 
cause local vasodilation and are preferred for vasopres-
sors, vinca alkaloids, phenytoin, and contrast media.14 
The local vasodilation is thought to increase blood flow, 
thereby augmenting drug disposal. Regardless of the 
lacking evidence, compresses are soothing to the patient 
and are recommended for that reason.
Support for manual extraction methods is sparse 
and anecdotal. Some reported interventions, such as the 
squeeze maneuver or the multiple puncture procedure, in-
volve using an 18-gauge needle to make 5–8 fenestrations 
at the peri-insertion area and subsequent compression 
proximal to the extravasation to liberate the infiltrated 
vesicant in adult infiltrations.18,19 Early subcutaneous wash-
out has been documented to be quite successful especially 
within 6 hours of the extravasation injury. In this method, 
isotonic saline is infiltrated through a liposuction cannula. 
The fluid is then removed by careful suction through the 
cannula. This procedure is repeated until 300–500 mL has 
been removed in total.20 The success of washout may be 
due to a prompt reduction of the infiltrated agent’s con-
centration.
In cases of soft-tissue ischemia or necrosis, the area of 
injury should be protected with a nonadherent dressing, 
which provides a protective barrier. Topical antimicrobials 
or a wound gel are also routinely used to promote a moist 
wound environment. Reassessments are paramount by a 
plastic surgery or wound team to be sure no further seri-
ous injury is noted.
Pharmacologic Management
The propensity for damage and the subsequent man-
agement of an infiltration insult is highly dependent upon 
the physiochemical characteristics of the extravasated 
agent.21 Those most commonly associated with extravasa-
tions will be described below.
Vasopressors
Extravasation by vasopressors (vasopressin, norepineph-
rine, epinephrine, dopamine, and dobutamine) causes 
local vasoconstriction, resulting in tissue ischemia and ne-
crosis6 (Figs. 1, 2). Though ordinarily administered via large 
central veins,22 peripheral infusion of vasopressors is some-
times performed to hasten the placement of IV access.22
Table 1. Symptoms of IV Extravasation2,3
1. Blanched skin that may feel cool to the touch
2. Pressure, swelling, a patient saying skin feels “tight”
3. Discomfort, pain, and tenderness
4. Insertion site edema
5. Alterations to the IV flow
6. Leakage of infused fluid at the insertion site
Table 2. Common Terminology Criteria for Adverse Events: 
Grading System for IV Extravasation Injuries12
1. Intact skin
2. Blanched skin, erythema
3. Necrosis or ulceration causing severe tissue damage; indicates 
surgical intervention
4. Life-threatening consequences; indicates immediate intervention
5. Death
Table 3. The Peripheral Intravenous Infiltration and 
Extravasation Scale used in Pediatric Infiltration and 
Extravasation Injuries (Adapted from Scale Originally by 
Children’s Medical Center of Dallas)13
1. Mild
 a. Swelling < 30%
 b. No blistering
 c. Normal, blanched skin
2. Moderate
 a. Swelling 30–60%
 b. Diminished pulse distal to IVT infiltration
 c. Close monitoring and follow-up
3. Severe
 a. 60%
 b. Fasciotomy or debridement
 c. Full-thickness skin loss
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Vasoconstriction occurs via an α-1–mediated response, 
with norepinephrine being the most commonly reported 
cause of vasopressor-mediated infiltration.14 Dopamine 
and epinephrine (β-1, β-2, and α-1 agonist) also func-
tion on α-1 receptors. Phentolamine may serve as a local 
therapy/reversal agent in these cases23,24 (Figs. 2, 3). In a 
study of 734 patients receiving peripheral intravenous va-
sopressors, there was a 2% incidence of infiltration.25 In 
all cases, local phentolamine was injected in addition to 
application of a nitroglycerin paste, and no patients expe-
rienced irreversible tissue necrosis. In contrast, vasopres-
sin exerts its vasoactive properties via the V1 receptor, and 
there are currently no reports of successful intervention 
with a direct reversal agent. Phentolamine, terbutaline, or 
topical nitroglycerin may provide some protective effect 
in vasopressin infiltrations via their inherent vasodilatory 
effects.14
Phentolamine is a reversible alpha-adrenergic receptor 
antagonist.14 For neonates, the provider should perform a 
1:10 dilution of the commercial 5 mg/mL phentolamine 
to a concentration of 0.5 mg/mL, followed by 5 injections 
of 0.2 mL of phentolamine into the area of extravasation.19 
For infants, children, and adults, 5 mg of phentolamine 
reconstituted with 5 mL of normal saline (1 mg/mL) or 
a 1:5 dilution should be performed of the commercially 
available 5 mg/mL phentolamine to attain a final concen-
tration of 1 mg/mL phentolamine. The solution should 
be injected in 0.5–1 mL aliquots 5 times around the in-
jection site using a 25-gauge or 27-gauge needle.25 Phen-
tolamine’s effects are time dependent with no beneficial 
outcome observed after 13 hours of the injury14 (Fig. 4). 
Nitroglycerin can be given to augment phentolamine-me-
diated vasodilation. Topical application of 2.5 cm of 2% 
nitroglycerin paste with reapplication every 8 hours has 
been shown to initiate reperfusion.14
Osmotically Active Agents
Infiltration of hypertonic solutions [TPN, peripheral 
parenteral nutrition (PPN), dextrose > 10%, sodium bi-
carbonate, potassium, and calcium 26) causes an imbal-
ance in the equilibrium between the intracellular and 
extracellular compartments, causing fluid shifts, cellular 
dysfunction, and cell damage/death. Accumulation of flu-
id further compromises the tissue compartment through 
hypoperfusion and subsequent tissue necrosis14 (Fig. 5). A 
retrospective study on 352 patients receiving PPN found 
a 40% incidence of phlebitis or infiltration. Those receiv-
ing PPN with osmolarity greater than 1,000 mOsm/L had 
a 17% incidence versus 7% incidence in patients receiv-
ing PPN with an osmolarity less than 1,000 mOsm/L.27 In 
these cases, the patient must be evaluated and monitored 
for compartment syndrome, with a low threshold to ob-
tain a compartment pressure or perform fasciotomies if 
clinically suspicious (positive if greater than 30 mm Hg).28
Hyaluronidase is often utilized for treating hypertonic 
extravasations, though not Food and Drug Administration 
(FDA) approved for this indication.14 Although there are 
conflicting data regarding its efficacy, most case studies 
report that hyaluronidase augments dispersion of the ex-
travasated agent.29 However, no randomized clinical studies 
have been performed to date.30 Hyaluronidase functions 
via depolymerization of glycosaminoglycans such as chon-
droitin sulfate and hyaluronic acid, which is thought to 
increase tissue permeability and subsequently aid in disper-
sion of the infiltrated agent (technique described below 
under cytotoxic drugs section). Local injection of hyaluron-
idase and saline washout is the current principle modality 
to treat severe TPN-associated extravasations; however, this 
is based on limited studies14 (Fig. 5). Hyaluronidase was 
shown to be successful in the treatment of 2 cases of TPN 
extravasations with improvement in 6–12 hours.31
Fig. 1.  a 11-year-old female with dopamine extravasation 5 days 
post infusion. treated with warm compress and phentolamine.
Fig. 2. a 32-week premature infant with a dopamine extravasation 2 
months post infusion.
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Contrast Media
Contrast media extravasation carries an incidence of 
0.1–0.9%32,33 and is usually minor and self-resolving; how-
ever, it can escalate to more serious complications.32,34 
Extravasated contrast media is toxic to the surrounding 
tissues and is associated with an inflammatory response 
that peaks between 24 and 48 hours.32 The mechanism of 
toxicity is similar to that of osmotically active agents, as its 
hypertonicity results in fluid shifts.32
There is no evidence-based consensus on manage-
ment; however, most commonly, the limb is elevated 
and treated with a warm compress.33 The efficacy of this 
maneuver is not proven.16,32 The attempted aspiration of 
contrast media, liposuction, or injection of local therapies 
such as hyaluronidase or corticosteroids has no evidential 
support for the treatment of a contrast media extravasa-
tion.32 As in all extravasation injuries, monitoring of the 
patient for progression of symptoms, such as progressive 
Fig. 3. a, a 5-day old full-term neonate with an R lower leg iV extravasation; dopamine and PPn were 
infusing. treated initially with phentolamine and elevation. B, 30-day Status post healing by secondary 
intention, with residual cosmetic skin changes.
Fig. 4. a, Severe epinephrine extravasation injury to the neck. therapies including subcutaneous phen-
tolamine and topical nitroglycerin paste were utilized after identification. nevertheless, substantial ir-
reversible tissue ischemia occurred, possibly due to a delay in identification. B, Debridement of necrotic 
skin and subcutaneous tissue was performed.
Fig. 5. a 3-month-old infant with a tPn infiltrate 1 week post infu-
sion. treated with hyaluronidase and elevation.
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neurologic or vascular complications, is appropriate and 
necessary.33
Cytotoxic Drugs
Cytotoxic drugs are grouped into 5 categories: ir-
ritants, inflammitants, exfoliants, vesicants, and neu-
trals (Table 4),11 with each causing characteristic clinical 
pictures of soft-tissue damage. Below, we will review the 
described pharmacologic interventions for these chemo-
therapeutic extravasations.
Hyaluronidase
Hyaluronidase degrades glycosaminoglycans and 
hyaluronic acid, with subsequent increases in tissue 
permeability and dispersion of extravasated agent.11,14 Hy-
aluronidase has been used for extravasation by etoposide, 
taxanes (ie, paclitaxel, docetaxel, and cabazitaxel), and 
vinca alkaloids.11 Although hyaluronidase is recognized as 
therapeutic for extravasation, there is much inconsistency 
with regard to proper technique and dosage. Additionally, 
there is a dearth of controlled, nonanecdotal studies prov-
ing its efficacy.
Rat studies have shown hyaluronidase to be effective 
at reducing the wound size and healing time in vinorel-
bine-induced extravasations.35 In 1994, hyaluronidase was 
also effective at preventing necrosis in 7 patients with ac-
cidental vinca alkaloid extravasation.36 Despite the poor 
evidence-based strength of recommendation, it is worth 
noting that the manufacturers of vinblastine indicate the 
use of hyaluronidase if extravasation occurs.37,38
Recent guidelines, especially for chemotherapeutic ex-
travasations in adults, recommend a dosage of 150 units 
of hyaluronidase.30 However, dosage varies among insti-
tutions. For Amphadase (Amphastar Pharmaceuticals, 
Rancho Cucamonga, Calif.), Hydase (Akorn, Lake For-
est, Ill.), and Hylenex (Baxter Healthcare Corporation, 
Deerfield, Ill.), vials contain 150 units/mL, which do not 
need further dilution.30 Vitrase (ISTA Pharmaceuticals, 
Irvine, Calif.) contains 2 mL of 200 units hyaluronidase, 
which should be further diluted in a 3:1 ratio of vitrase to 
normal saline (0.75 mL of vitrase solution with 0.25 mL of 
normal saline). Hyaluronidase (150 unit in 1 mL) should 
be administered through five 0.2 mL subcutaneous injec-
tions into the extravasation site.
For pediatric patients, it has been shown that the ad-
ministration of 15 units of hyaluronidase is effective to 
resolve the extravasation.19 This dilution is achieved with 
0.1 mL (150 unit/mL) hyaluronidase solution with 0.9 mL 
of normal saline, yielding the desired 15 units/mL for in-
jection. The administration should be done immediately, 
with benefit seen when given within 3 hours of insult. In 
pediatric patients or infants, a 27–30 gauge needle is used 
to inject five 0.2 mL injections of hyaluronidase around 
the infiltration site in a circular pattern.19,30,39
Dexrazoxane Hydrochloride
Dexrazoxane [Zinecard (Pfizer, New York City), Savene 
and Totect (Clinigen Group Plc, Burton-on-Trent, United 
Kingdom)] is an FDA-approved local therapy for anthracy-
cline (daunorubicin, doxorubicin) extravasation,11 which 
commonly results in severe tissue damage. Its mode of 
action is not well understood.11,40 Two prospective clinical 
trials, TT01 and TT02, were conducted to determine the 
efficacy and tolerability of treatment with dexrazoxane 
[Savene (Clinigen Group Plc, Burton-on-Trent, United 
Kingdom)]. These studies, unlike other extravasation 
studies, used fluorescence biopsies to objectify the diagno-
sis of extravasation.41 Fifty-four patients were confirmed to 
have anthracycline extravasation. The 54 patients under-
went dexrazoxane treatment: 1,000 mg/m2 within 6 hours 
of insult, 1,000 mg/m2 24 hours after initial treatment, 
and 500 mg/m2 48 hours after initial treatment.41 Of the 
54 patients receiving treatment, only 1 patient required 
a surgical intervention, an efficacy rate of 98%.41,42 In ad-
dition, over two-thirds the patients had no resultant delay 
in chemotherapeutic treatment secondary to soft-tissue 
wounds.41,42
Indication for dexrazoxane administration is extrava-
sation of more than 5 mL of an anthracycline drug.9 It is 
contraindicated in the following patient populations: less 
than 18 years old, hepatic or renal insufficiency, recent 
inoculation with a live vaccine, and patients receiving phe-
nytoin.9,43 It may also be teratogenic and should be avoid-
ed during pregnancy.44
The treatment consists of a 3-day course of IV dexra-
zoxane.45 The first dose of 1,000 mg/m2 is ideally adminis-
tered as soon as possible, followed by 1,000 mg/m2 on day 
2, and 500 mg/m2 on day 3.15,43,45
Concomitant administration of dimethyl sulfoxide 
(DMSO) is not recommended,15,43,46 as this has been asso-
ciated with an increased occurrence of wounds.43
DMSO
DMSO is a topical organosulfur solvent that increases 
skin permeability and, therefore, augments absorption 
and subsequent dispersion of the extravasated agent,11,30,47 
and functioning as a free-radical scavenger.11 Ninety-nine 
percentage of DMSO is applied topically and may improve 
outcomes for smaller anthracycline extravasations. It was 
shown to be effective in resolving anthracycline extravasa-
tion in a prospective pilot trial of 20 patients. No patient 
required surgical intervention or had lesion formation.48 
However, there is a lack of evidence using objective fluo-
rescence biopsy data, and thus routine use in anthracy-
cline extravasation remains controversial.47 However, 
Table 4.  Classes of Cytotoxic Drugs2,9




Inflammation, blistering of 





Inflammation and blistering, 













Inert, no inflammation or 
direct tissue damage
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DMSO in conjunction with cold compresses remains the 
most common acute therapy minor anthracycline extrava-
sation, particularly if dexrazoxane is not available.11
DMSO should be implemented within the first 10–25 
minutes of extravasation,9 while minimizing exposure to 
unaffected skin, followed by hydrocortisone if erythema is 
present,9 and then a cold compress. This process should 
be repeated every 2 hours for the first day, after which the 
frequency is reduced.9
Sodium Thiosulfate
Sodium thiosulfate functions as an additional target 
for alkylation and can hypothetically neutralize certain 
vesicants, specifically mechlorethamine (nitrogen mus-
tard, no longer commercially available) or concentrated 
cisplatin.49–51 However, while many providers report the 
use of sodium thiosulfate, no randomized clinical trials 
have been conducted on its efficacy.51
When administered, sodium thiosulfate is injected sub-
cutaneously in a pinwheel fashion around the affected tis-
sue. Four to 8 mL of 10% sodium thiosulfate is mixed with 
6 mL of sterile water.50 Two milliliter of sodium thiosulfate 
solution is injected for every milligram of mechloretha-
mine or 100 milligrams of cisplatin infiltrated.
Gault Method
The Gault Method of saline washout for extravasation 
injuries was first described in 1993.26 This method involves 
early saline washout with subsequent liposuction via a 
small incision. Forty-four of the 96 patients studied un-
derwent early washout. Eighty-six percentage healed with 
no soft tissue loss compared with 15% in the late referral 
group. In areas with less subcutaneous fat, Gault describes 
injection 1 unit of hyaluronidase. This is followed by mak-
ing 4 small incisions surrounding the extravasated area. Fi-
nally, the extravasation area is flushed with normal saline, 
resulting in irrigation of subcutaneous tissue and efflux 
through the previously placed incisions.26
Dressings
In the event of tissue necrosis, the wound should be 
dressed in a manner to promote a moist, clean, and warm 
environment, while removing excess exudate.52,53 Eschar 
and necrotic tissue can impair reepithelialization and 
strong consideration should be given to debridement 
once the extent of tissue death has demarcated.54 Plain 
gauze (wet to dry dressings), while beneficial in debrid-
ing the wound bed on removal, can also traumatize viable 
healthy tissue, be painful, and needs frequent dressing 
changes to be effective. Nonadherent dressings [ie, Xe-
roform (Tyco Healthcare/Kendall, Mansfield, Mass.) and 
Adaptic [Johnson and Johnson, Somerville, N.J.)] can 
maintain a moist environment in epithelializing wounds 
and reduce pain with dressing changes, however should 
be changed daily to prevent them from drying and trau-
matizing the tissue bed on removal. Hydrocolloid dress-
ings [DuoDERM (Convatec, Bridgewater, N.J.), Exuderm 
(Medline, Havre de Grace, MD), Comfeel (Coloplast, 
Minneapolis, Minn.), etc] can absorb mild amounts of ex-
udate, maintain a moist environment, and minimize skin 
trauma with dressing changes. They have been shown to 
be of benefit in the neonatal population.55 Wounds with 
higher degrees of exudate may require more absorptive 
dressings such as alginates or hydrofibers.
Surgical Management
In the majority of instances, conservative manage-
ment is successful, as only 1 in 3 vesicants results in ul-
ceration.56 Surgical management may become indicated 
if soft-tissue necrosis develops. Healing capability is typi-
cally impaired due to a lack of granulation tissue and 
restricted epithelial ingrowth resulting in ulcer progres-
sion.56 In patients undergoing chemotherapeutic treat-
ment, open wounds may present an increased infection 
risk and delays in treatment. A discussion between medi-
cal oncologists and the surgical team is critical to deter-
mine the optimal treatment course and timeframe for 
the patient.
Debridement (with or without reconstruction) is indi-
cated if extravasation results in continuous pain (persist-
ing for 1–2 weeks), persistent ulceration, or full-thickness 
skin necrosis.9,11,14,15,46,57 Fasciotomy is the treatment of 
choice if compartment syndrome develops.6,41
CONCLUSIONS
Iatrogenic injuries secondary to intravenous extrava-
sation are commonplace in hospitals. In severe cases, 
limb loss is a potential consequence of poor or delayed 
management. Nursing algorithms for management of 
extravasation injuries are usually directed toward con-
sultation of a wound care team immediately after identi-
fication, who may implement local interventions in the 
appropriate time-sensitive manner. Hospitals without a 
dedicated wound care team trained in these interven-
tions will often default to plastic surgical consultation, 
making an understanding of available interventions 
essential to the initial evaluation and management of 
these injuries. Guidelines for the treatment of extrava-
sation injuries facilitate decision making, given their 
time-sensitive nature. Appropriate immediate manage-
ment may reduce further damage, limb loss, and even 
avoid potential litigation. Although there is no stan-
dardized protocol for extravasations injuries, a pro-
posed treatment algorithm is shown in Supplemental 
Digital Content 1.
The goal of this article was to provide plastic sur-
geons and trainees with a comprehensive overview of the 
acute management of intravenous extravasation injuries. 
Our hope is that this will serve as an effective resource 
for caregivers treating acute extravasation injuries (See 
figure, Supplemental Digital Content 1, which displays 
the treatment algorithm, http://links.lww.com/PRSGO/
A724). Though the decision for surgical versus nonsurgi-
cal management is often a clear one for plastic surgeons, 
local interventions, and therapies are often indicated and 
under-utilized in the immediate postextravasation period. 
Thorough knowledge of these interventions should be a 
basic requirement in the armamentarium of plastic sur-
gery consultants.
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